IN2014DN07799A - - Google Patents
Info
- Publication number
- IN2014DN07799A IN2014DN07799A IN7799DEN2014A IN2014DN07799A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A IN 7799DEN2014 A IN7799DEN2014 A IN 7799DEN2014A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A
- Authority
- IN
- India
- Prior art keywords
- antibody
- present disclosure
- rob04
- angiogenesis
- pharmaceutical composition
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 4
- 230000003527 anti-angiogenesis Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (ja) | 2012-04-27 | 2012-04-27 | 抗ｒｏｂｏ４抗体 |
| JP2013011042A JP2014141434A (ja) | 2013-01-24 | 2013-01-24 | 抗ｒｏｂｏ４抗体 |
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07799A true IN2014DN07799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-05-15 |
Family
ID=48670623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7799DEN2014 IN2014DN07799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-04-27 | 2013-04-26 |
Country Status (22)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2682451C2 (ru) * | 2012-04-27 | 2019-03-19 | Дайичи Санкио Компани, Лимитед | Антитела к robo4 |
| RS65415B1 (sr) | 2015-09-24 | 2024-05-31 | Daiichi Sankyo Co Ltd | Anti-garp antitelo |
| US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
| KR20210070643A (ko) | 2019-12-05 | 2021-06-15 | 김명배 | 자체 발전 웨어러블 다리 |
| US20250066471A1 (en) | 2022-02-16 | 2025-02-27 | Institut National de la Santé et de la Recherche Médicale | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| WO2025045139A1 (zh) * | 2023-08-31 | 2025-03-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别robo2的抗体及其应用 |
| CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2314685B1 (en) | 2000-10-06 | 2017-09-20 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| WO2002036771A2 (en) | 2000-11-06 | 2002-05-10 | Cancer Research Technology Limited | Imaging, diagnosis and treatment of disease |
| JP4583638B2 (ja) * | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | アセチルリジン認識モノクローナル抗体及びその製造方法 |
| EP1534318A4 (en) | 2002-06-27 | 2009-07-01 | Univ Utah Res Found | METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS |
| JP4869603B2 (ja) | 2002-11-20 | 2012-02-08 | キャンサー・リサーチ・テクノロジー・リミテッド | 抗体、ポリペプチドおよびその使用 |
| NZ541458A (en) | 2003-01-07 | 2006-04-28 | Symphogen As | Method for manufacturing recombinant polyclonal proteins |
| KR20090089462A (ko) | 2006-12-11 | 2009-08-21 | 유니버시티 오브 유타 리써치 파운데이션 | 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 |
| WO2008100805A2 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| RU2682451C2 (ru) * | 2012-04-27 | 2019-03-19 | Дайичи Санкио Компани, Лимитед | Антитела к robo4 |
-
2013
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/ru not_active IP Right Cessation
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/ko not_active Expired - Fee Related
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/ko not_active Ceased
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/ja not_active Expired - Fee Related
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 ES ES13730645T patent/ES2733434T3/es active Active
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en active Application Filing
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/pt not_active Application Discontinuation
- 2013-04-26 PL PL13730645T patent/PL2841457T3/pl unknown
- 2013-04-26 TW TW102115219A patent/TWI606065B/zh not_active IP Right Cessation
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 MX MX2014012351A patent/MX356749B/es active IP Right Grant
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/da active
- 2013-04-26 US US14/397,210 patent/US9683040B2/en not_active Expired - Fee Related
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/zh not_active Expired - Fee Related
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382A1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/es unknown
-
2015
- 2015-12-11 US US14/966,292 patent/US9562096B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| HUE049171T2 (hu) | Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek | |
| EP3421496C0 (en) | ANTIBODIES FOR THE TREATMENT OF CLAUDIN-6-EXPRESSING CANCER | |
| EP2761554A4 (en) | PAYMENTS IN SOCIAL PROXIMITY | |
| EP2786664A4 (en) | METHOD OF MANUFACTURING PULLE FOR ELECTRONIC SMOKE SET AND TRADITIONAL WATER PIPE | |
| EP2863910A4 (en) | COMPOSITIONS AND METHOD FOR REGULATING GLUCOSE-HOMOSTOSTASE AND INSULIN EFFECT | |
| IL244319A0 (en) | Methods and systems for continuous propagation and mass production of arbuscular mycorrhizal fungi in liquid culture | |
| AU341611S (en) | Dual function wine system | |
| UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
| MX2015010429A (es) | Cetuximab con glicosilación modificada y sus usos. | |
| EP2832694A4 (en) | DDR ZEOLITHIMPFKRISTALL, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF A DDR ZEOLITHFILMS | |
| IN2014MN02114A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP2742400A4 (en) | CANCELLATION AND / OR DRIVING OF CONNECTIONS FOR ASSOCIATED EMPLOYMENT OPERATIONS | |
| MX2014004211A (es) | Composiciones de recubrimiento para moldes y machos de fundicion inorganicos que comprenden esteres de acido formico y uso de los mismos. | |
| EP2771688A4 (en) | FREE PSA ANTIBODY AS A MEDIUM FOR DIAGNOSIS, FORECAST AND THERAPY OF PROSTATE CANCER | |
| EP3031914A4 (en) | MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME | |
| AU343147S (en) | Easel | |
| EP2714923A4 (en) | METHOD AND COMPOSITIONS FOR DETECTING FUNCTIONAL CLOSTRIDIUM DIFFICILE TOXINS | |
| EP3049142A4 (en) | CATHETER ADDITIVE AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| IL243727A0 (en) | A system and method for obtaining changes in material properties from stored and decoded signals over time for the purpose of predicting future changes in conventional predictors | |
| MX2016005645A (es) | Composicion farmaceutica topica de acitretina. | |
| EP2687222A4 (en) | Bleomycin hydrolase production promoting agent | |
| BR112013032496A2 (pt) | método de fermentação de abe compreendendo absorção do produto através de isoforona | |
| PL2994455T3 (pl) | Sposób i proces techniczny ciągłej syntezy różnych cieczy jonowych | |
| IN2014MN01871A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |